Raymond E. Cabillot Sells 7,674 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 7,674 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $45.00, for a total transaction of $345,330.00. Following the transaction, the director now directly owns 310,978 shares of the company’s stock, valued at approximately $13,994,010. This trade represents a 2.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Pro-Dex Stock Up 7.7 %

NASDAQ:PDEX traded up $3.41 during trading hours on Tuesday, hitting $47.78. The company’s stock had a trading volume of 66,240 shares, compared to its average volume of 32,979. Pro-Dex, Inc. has a 52-week low of $16.83 and a 52-week high of $59.60. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $155.81 million, a P/E ratio of 23.77 and a beta of 0.68. The stock has a fifty day moving average of $39.93 and a 200-day moving average of $37.76.

Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. On average, equities analysts forecast that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on PDEX. Ascendiant Capital Markets increased their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. StockNews.com lowered Pro-Dex from a “strong-buy” rating to a “buy” rating in a report on Monday, February 3rd.

Institutional Trading of Pro-Dex

Several institutional investors have recently modified their holdings of the stock. Northern Trust Corp grew its position in shares of Pro-Dex by 14.1% in the 4th quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock valued at $1,672,000 after buying an additional 4,426 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after purchasing an additional 2,296 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after purchasing an additional 529 shares during the last quarter. EAM Investors LLC acquired a new stake in shares of Pro-Dex in the 4th quarter valued at about $1,047,000. Finally, O Shaughnessy Asset Management LLC purchased a new position in Pro-Dex during the 4th quarter worth approximately $995,000. Hedge funds and other institutional investors own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.